Nuvalent (NUVL) Cash from Operations (2020 - 2026)
Nuvalent (NUVL) reported Cash from Operations of 92399000.0 for Q1 2026, down 68.55% on a YoY basis from 293765909.59 in Q1 2025, and down 26.01% quarter-over-quarter from 73328000.0 in Q4 2025.
Nuvalent (NUVL) Cash from Operations (2020 - 2026) Analysis & Trends
Nuvalent has reported Cash from Operations for 7 years, with the latest figure at 92399000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 68.55% year-over-year to 92399000.0; the trailing twelve-month figure through Mar 2026 stood at 312787000.0 (down 53.48% YoY), and the FY2025 full-year result was 275209000.0, down 48.71% from the prior year.
- Cash from Operations for Q1 2026 stood at 92399000.0, down from 73328000.0 in the prior quarter.
- The five-year high for Cash from Operations was 13542000.0 in Q1 2022, with the low at 92399000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 42198941.18 across 5 years, with a median of 36087000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 128.25% — and 2025, when it retreated 18.27%.
- Nuvalent's Cash from Operations stood at 17779000.0 in 2022, then plunged by 69.91% to 30209000.0 in 2023, then plunged by 105.24% to 62000000.0 in 2024, then dropped by 18.27% to 73328000.0 in 2025, then slipped by 26.01% to 92399000.0 in 2026.
- The last three Cash from Operations figures came in at 92399000.0 (Q1 2026), 73328000.0 (Q4 2025), and 70462000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -92.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.40 Mn |
| Mar 31, 2026 | -92.40 Mn |
| Dec 31, 2025 | -73.33 Mn |
| Dec 31, 2025 | -73.33 Mn |
| Sep 30, 2025 | -70.46 Mn |
| Sep 30, 2025 | -70.46 Mn |
| Jun 30, 2025 | -76.60 Mn |
| Jun 30, 2025 | -76.60 Mn |
| Mar 31, 2025 | -54.82 Mn |
| Mar 31, 2025 | -54.82 Mn |
| Dec 31, 2024 | -62.00 Mn |
| Dec 31, 2024 | -62.00 Mn |
| Sep 30, 2024 | -45.82 Mn |
| Sep 30, 2024 | -45.82 Mn |
| Jun 30, 2024 | -41.16 Mn |
| Jun 30, 2024 | -41.16 Mn |
| Mar 31, 2024 | -36.09 Mn |
| Mar 31, 2024 | -36.09 Mn |
| Dec 31, 2023 | -30.21 Mn |
| Dec 31, 2023 | -30.21 Mn |